Colorectal Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Combined inactivation of the microRNA 34a gene (MIR34A, by methylation) and the TP53 gene (by mutation or deletion) is observed in 50% of colorectal tumors that progress to distant metastases.
|
30099074 |
2018 |
Colorectal Neoplasms
|
0.700 |
Therapeutic
|
group |
RGD |
Matrine Ameliorates Colorectal Cancer in Rats via Inhibition of HMGB1 Signaling and Downregulation of IL-6, TNF-α, and HMGB1.
|
29546074 |
2018 |
Colorectal Neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
However, p53 immunoreactivity was correlated with shorter PFS in patients with colorectal tumors (HR = 2.1, p = 0.03) in a univariate analysis as well as to poorer PFS (HR = 2.6, p = 0.03) and OS (HR = 3.4, p = 0.02) in patients with colorectal tumors with distant metastases, a correlation which remained significant in the multivariate analyses.
|
29112960 |
2017 |
Colorectal Neoplasms
|
0.700 |
AlteredExpression
|
group |
BEFREE |
In this study, we investigated the clinicopathologic significance of TUFM and p53 expression for the normal-adenoma-carcinoma sequence in colorectal epithelia and evaluated the roles of TUFM during the progression of colorectal tumors.
|
28449687 |
2017 |
Colorectal Neoplasms
|
0.700 |
GeneticVariation
|
group |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
Colorectal Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
TP53 was the most commonly mutated gene, with prevalence similar to that of sporadic colorectal tumors (63% of cases).
|
26764183 |
2016 |
Colorectal Neoplasms
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Human colorectal tumors with wild-type TP53 and high PBF expression also had low p53 protein levels (P < 0.05), further emphasizing a putative interaction between these genes in vivo.
|
25408419 |
2016 |
Colorectal Neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
Multiplex Ligation-dependent Probe Amplification, TP53 sequencing, real-time polymerase chain reaction (PCR) for MUC1 and SCGB2A2 and immunocytochemistry, together with senescence detection assay and real-time microscopic observations were used to analyze primary neoplastic cells isolated from prostate, breast and colorectal tumors, as well as stable cancer cell lines (MCF7, MDA-MB-468, SW962, SK-MEL28, NCI-H1975 and NCI-H469).
|
25964555 |
2015 |
Colorectal Neoplasms
|
0.700 |
GeneticVariation
|
group |
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
Colorectal Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Heme iron intake was associated with an increased risk of colorectal tumors harboring G>A transitions in KRAS and APC and overexpression of P53.
|
23983135 |
2013 |
Colorectal Neoplasms
|
0.700 |
Biomarker
|
group |
CTD_human |
A germline variant in the TP53 polyadenylation signal confers cancer susceptibility.
|
21946351 |
2011 |
Colorectal Neoplasms
|
0.700 |
Biomarker
|
group |
LHGDN |
Trichostatin A causes p53 to switch oxidative-damaged colorectal cancer cells from cell cycle arrest into apoptosis.
|
18419600 |
2008 |
Colorectal Neoplasms
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Fhit, Mlh1, P53 and phenotypic expression in the early stage of colorectal neoplasms.
|
18097574 |
2008 |
Colorectal Neoplasms
|
0.700 |
GeneticVariation
|
group |
LHGDN |
Colorectal carcinomas from Middle East. Molecular and tissue microarray analysis of genomic instability pathways.
|
18176677 |
2008 |
Colorectal Neoplasms
|
0.700 |
Biomarker
|
group |
CTD_human |
The predictive value of p53 and p33(ING1b) in patients with Dukes'C colorectal cancer.
|
17949449 |
2008 |
Colorectal Neoplasms
|
0.700 |
AlteredExpression
|
group |
LHGDN |
Abberant crypt foci -- importance in colorectal carcinogenesis and expression of p53 and mdm2: a changing concept.
|
18080767 |
2008 |
Colorectal Neoplasms
|
0.700 |
AlteredExpression
|
group |
LHGDN |
Detection of colorectal cancer cells from feces using quantitative real-time RT-PCR for colorectal cancer diagnosis.
|
19016757 |
2008 |
Colorectal Neoplasms
|
0.700 |
GeneticVariation
|
group |
LHGDN |
We have analyzed the prevalence of MDM2 gene amplifications and SNP309 in 284 colorectal tumors using a relatively new highly sensitive PCR/ligase detection reaction method in relation to TP53 mutational status and genomic instability.
|
18314481 |
2008 |
Colorectal Neoplasms
|
0.700 |
AlteredExpression
|
group |
LHGDN |
Inhibition of cell-cycle progression in human colorectal carcinoma Lovo cells by andrographolide.
|
18619950 |
2008 |
Colorectal Neoplasms
|
0.700 |
Biomarker
|
group |
LHGDN |
Proline oxidase, a p53-induced gene, targets COX-2/PGE2 signaling to induce apoptosis and inhibit tumor growth in colorectal cancers.
|
18794809 |
2008 |
Colorectal Neoplasms
|
0.700 |
GeneticVariation
|
group |
LHGDN |
GSTM, GSTT and p53 polymorphisms as modifiers of clinical outcome in colorectal cancer.
|
18630481 |
2008 |
Colorectal Neoplasms
|
0.700 |
Biomarker
|
group |
CTD_human |
K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy.
|
18676755 |
2008 |
Colorectal Neoplasms
|
0.700 |
GeneticVariation
|
group |
LHGDN |
Association of p53 codon 72 polymorphism with liver metastases of colorectal cancers positive for p53 overexpression.
|
18988302 |
2008 |
Colorectal Neoplasms
|
0.700 |
GeneticVariation
|
group |
LHGDN |
Genetic alterations of APC, K-ras, p53, MSI, and MAGE in Korean colorectal cancer patients.
|
17704924 |
2008 |
Colorectal Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
We have analyzed the prevalence of MDM2 gene amplifications and SNP309 in 284 colorectal tumors using a relatively new highly sensitive PCR/ligase detection reaction method in relation to TP53 mutational status and genomic instability.
|
18314481 |
2008 |